0

Drugs for HER2-positive Breast Cancer

Milestones in Drug Therapy

Erschienen am 07.01.2011, 1. Auflage 2011
160,49 €
(inkl. MwSt.)

Lieferbar innerhalb 1 - 2 Wochen

In den Warenkorb
Bibliografische Daten
ISBN/EAN: 9783034600934
Sprache: Englisch
Umfang: x, 110 S.
Einband: gebundenes Buch

Beschreibung

InhaltsangabeDrugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER-2-positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Inhalt

Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER-2-positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Weitere Artikel vom Autor "Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al"

Alle Artikel anzeigen